Connect your AI

Ginkgo Bioworks DNA Continuing operations (in dollars per share)

Continuing operations (in dollars per share) at other companies

AzentaAZTA

——

RevvityRVTY

——

Other financials

Income statement

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerBasicShare.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's continuing operations (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ginkgo Bioworks's continuing operations (in dollars per share)?: Ginkgo Bioworks (DNA) reported continuing operations (in dollars per share) of -$1.28 in Q1 2026.